CPI-1189

CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases[1][2][3][4][5].

Product Specifications

CAS Number

[183619-38-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cpi-1189.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC(C)(C)C)C1=CC=C(NC(C)=O)C=C1

Molecular Formula

C13H18N2O2

Molecular Weight

234.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Müller T. CPI-1189. Centaur. Curr Opin Investig Drugs. 2002 Dec;3 (12) :1763-7. |[2]Clifford DB, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002 Nov 26;59 (10) :1568-73.|[3]Li YJ, et al. CPI-1189 protects neuronal cells from oxygen glucose deprivation/re-oxygenation-induced oxidative injury and cell death. Aging (Albany NY) . 2021 Feb 17;13 (5) :6712-6723.|[4]Hensley K, et al. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281 (2-3) :179-82.|[5]Bjugstad KB, et al. Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 1998 Jun 8;795 (1-2) :349-57.